Investing

StreetInsider.com After-Hours Movers 05/02

YM BioSciences Inc. (AMEX: YMI) 20% HIGHER; announced top-line results from its randomized, placebo-controlled Phase IIb trial of AeroLEF in opioid naive patients with post-operative pain following orthopedic surgery. AeroLEF met the primary endpoint of the study, showing a statistically significant difference in SPRID4 from placebo (p=0.0194).

NVE Corp (Nasdaq: NVEC) 14% HIGHER; reports Q1 EPS of $0.33, 6 cents better than estimates.(0.27) Revenues were $4.57 million vs. $4.38 million consensus.

MINRAD International, Inc. (AMEX: BUF) 11% HIGHER; announced it has received approval from the FDA to market Sojourn inhalation anesthetic.

Sirenza Micro (Nasdaq: SMDI) 11% HIGHER; reports Q1 EPS of $0.12, 2 cents better than estimates.(0.10) Revenues were $39.1 million vs. $36.97 million consensus.

Axcelis Technologies (Nasdaq: ACLS) 10% LOWER; reports Q1 EPS of $0.03, 1 cent worse than estimates.(0.04) Revenues were $97.5 million vs. $97.04 million consensus. Sees Q2 EPS of $0.03-$0.07 versus the consensus of $0.09. Sees Q2 revs of $108-$118 million versus the consensus of $113.4 million.

JDS Uniphase (Nasdaq: JDSU) 9% LOWER; reports Q3 EPS of $0.06, 4 cents worse than estimates.(0.10) Revenues were $361.7 million vs. $346.54 million consensus. Sees Q4 revs of $325-$345M versus the consensus of $354.5M.

Smith Micro Software (Nasdaq: SMSI) 9% LOWER; reports Q1 EPS of $0.20, 3 cents better than estimates.(0.17) Revenues were $17.7 million vs. $17.52 million consensus

Andersons (Nasdaq: ANDE) 8% LOWER; reports Q1 earnings of $0.51 per share above the consensus of $0.33. Revenues came in at $409.1 million versus the consensus of $326.8 million. Sees FY07 EPS of $2.35-$2.60 versus the consensus of $2.71.

Maxwell Technologies (Nasdaq: MXWL) 8% LOWER; reports Q1 loss of $0.25, 1 cent worse than estimates.(-.24) Revenues were $12.6 million vs. $13.83 million consensus.

Aspreva Pharmaceuticals (Nasdaq: ASPV) 7% LOWER; reports Q1 EPS of $1.03, cents better than estimates.(0.87) Revenues were $59.3 million vs. $58.74 million consensus.

PeopleSupport (Nasdaq: PSPT) 7% LOWER; reports Q1 EPS of $0.16, 6 cents better than estimates.(0.10) Revenues were $33.6 million vs. $32.45 million consensus. Sees Q2 EPS of $0.01-$0.03 versus the consensus of $0.10. Sees Q2 revs of $31-$32 million versus the consensus of $33.72 million. Sees FY EPS of $0.27-$0.38 versus the consensus of $0.43. Sees FY07 revs of $133-$137 million versus the consensus of $140.2 million.

Symantec (Nasdaq: SYMC) 6% HIGHER; reports Q4 EPS of $0.24, 4 cents better than estimates.(0.20) Revenues were $1.36 billion vs. $1.27 billion consensus. Sees Q1 EPS of $0.18-$0.20, versus the consensus of $0.24. Sees FY08 EPS of $1.10-$1.15 versus the consensus of $1.09.

RealNetworks (Nasdaq: RNWK) 5.8% HIGHER; reports Q1 EPS of $0.22, 5 cents better than estimates.(0.17) Revenues were $129.5 million vs. $125.26 million consensus. Sees Q2 EPS of $0.04-$0.06, versus the consensus of $0.00. Sees FY EPS of $0.23-$0.25 versus the consensus of $0.22. Sees FY revs of $547-$563M versus the consensus of $550.4M.

SuperGen (Nasdaq: SUPG) 5.8% LOWER; reports Q1 loss of $0.06, versus the consensus of a $0.02 profit. Revenues were $4.4 million vs. $10.93 million consensus.

Blackboard (Nasdaq: BBBB) 5% HIGHER; reports Q1 EPS of $0.07, 2 cents better than estimates.(0.05) Revenues were $55.3 million vs. $53.6 million consensus. Sees Q2 EPS of $0.08-$0.10, versus the consensus of $0.07. Sees FY EPS of $0.35-$0.41 versus the consensus of $0.39.

TASER (Nasdaq: TASR) 4.8% HIGHER; Jim Cramer said if conversative candidate Sarkozy wins the French Presidential election he promised to put a TASER in every police car in France

YM BioSciences Inc. (AMEX: YMI) 20% HIGHER; announced top-line results from its randomized, placebo-controlled Phase IIb trial of AeroLEF in opioid naive patients with post-operative pain following orthopedic surgery. AeroLEF met the primary endpoint of the study, showing a statistically significant difference in SPRID4 from placebo (p=0.0194).

NVE Corp (Nasdaq: NVEC) 14% HIGHER; reports Q1 EPS of $0.33, 6 cents better than estimates.(0.27) Revenues were $4.57 million vs. $4.38 million consensus.

MINRAD International, Inc. (AMEX: BUF) 11% HIGHER; announced it has received approval from the FDA to market Sojourn inhalation anesthetic.

Sirenza Micro (Nasdaq: SMDI) 11% HIGHER; reports Q1 EPS of $0.12, 2 cents better than estimates.(0.10) Revenues were $39.1 million vs. $36.97 million consensus.

Axcelis Technologies (Nasdaq: ACLS) 10% LOWER; reports Q1 EPS of $0.03, 1 cent worse than estimates.(0.04) Revenues were $97.5 million vs. $97.04 million consensus. Sees Q2 EPS of $0.03-$0.07 versus the consensus of $0.09. Sees Q2 revs of $108-$118 million versus the consensus of $113.4 million.

JDS Uniphase (Nasdaq: JDSU) 9% LOWER; reports Q3 EPS of $0.06, 4 cents worse than estimates.(0.10) Revenues were $361.7 million vs. $346.54 million consensus. Sees Q4 revs of $325-$345M versus the consensus of $354.5M.

Smith Micro Software (Nasdaq: SMSI) 9% LOWER; reports Q1 EPS of $0.20, 3 cents better than estimates.(0.17) Revenues were $17.7 million vs. $17.52 million consensus

Andersons (Nasdaq: ANDE) 8% LOWER; reports Q1 earnings of $0.51 per share above the consensus of $0.33. Revenues came in at $409.1 million versus the consensus of $326.8 million. Sees FY07 EPS of $2.35-$2.60 versus the consensus of $2.71.

Maxwell Technologies (Nasdaq: MXWL) 8% LOWER; reports Q1 loss of $0.25, 1 cent worse than estimates.(-.24) Revenues were $12.6 million vs. $13.83 million consensus.

Aspreva Pharmaceuticals (Nasdaq: ASPV) 7% LOWER; reports Q1 EPS of $1.03, cents better than estimates.(0.87) Revenues were $59.3 million vs. $58.74 million consensus.

PeopleSupport (Nasdaq: PSPT) 7% LOWER; reports Q1 EPS of $0.16, 6 cents better than estimates.(0.10) Revenues were $33.6 million vs. $32.45 million consensus. Sees Q2 EPS of $0.01-$0.03 versus the consensus of $0.10. Sees Q2 revs of $31-$32 million versus the consensus of $33.72 million. Sees FY EPS of $0.27-$0.38 versus the consensus of $0.43. Sees FY07 revs of $133-$137 million versus the consensus of $140.2 million.

Symantec (Nasdaq: SYMC) 6% HIGHER; reports Q4 EPS of $0.24, 4 cents better than estimates.(0.20) Revenues were $1.36 billion vs. $1.27 billion consensus. Sees Q1 EPS of $0.18-$0.20, versus the consensus of $0.24. Sees FY08 EPS of $1.10-$1.15 versus the consensus of $1.09.

RealNetworks (Nasdaq: RNWK) 5.8% HIGHER; reports Q1 EPS of $0.22, 5 cents better than estimates.(0.17) Revenues were $129.5 million vs. $125.26 million consensus. Sees Q2 EPS of $0.04-$0.06, versus the consensus of $0.00. Sees FY EPS of $0.23-$0.25 versus the consensus of $0.22. Sees FY revs of $547-$563M versus the consensus of $550.4M.

SuperGen (Nasdaq: SUPG) 5.8% LOWER; reports Q1 loss of $0.06, versus the consensus of a $0.02 profit. Revenues were $4.4 million vs. $10.93 million consensus.

Blackboard (Nasdaq: BBBB) 5% HIGHER; reports Q1 EPS of $0.07, 2 cents better than estimates.(0.05) Revenues were $55.3 million vs. $53.6 million consensus. Sees Q2 EPS of $0.08-$0.10, versus the consensus of $0.07. Sees FY EPS of $0.35-$0.41 versus the consensus of $0.39.

TASER (Nasdaq: TASR) 4.8% HIGHER; Jim Cramer said if conversative candidate Sarkozy wins the French Presidential election he promised to put a TASER in every police car in France

Get Ready To Retire (Sponsored)

Start by taking a quick retirement quiz from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes, or less.

Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.

Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future

Get started right here.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.